SOURCE: Rheologics Technologies, Inc.

January 25, 2007 21:57 ET

Rheologics Blood Viscosity Testing Update

EXTON, PA -- (MARKET WIRE) -- January 25, 2007 -- Rheologics, Inc., a subsidiary of Rheologics Technologies, Inc. (PINKSHEETS: RTGI) ("Rheologics"), the leader in the study of blood viscosity and its relationship to cardiovascular disease, is pleased to announce that its Laboratory Services unit has received an encouraging number of requests for its Whole Blood Viscosity (WBV) testing program. The Company believes that in addition to gathering important clinical data, the initial response indicates a strong demand for the service.

For physicians, general practitioners, and internists, knowing the viscosity of their patients' blood provides a critical tool in evaluating the efficiency and health of a cardiovascular system. The role that blood viscosity plays in cardiovascular health is substantial. Since the cardiovascular system is a closed system, the viscosity or thickness of what the heart is pumping directly affects the heart's efficiency and the damage done to the arteries by blood flow.

As part of the program, patients' blood specimens are drawn at their physicians' offices into standard vacutainers and shipped overnight in a cold pack to Rheologics' laboratory facility in Exton, Pennsylvania. Rheologics provides physicians with the specimen collection kits used for convenient packing and shipping. Test results include a graph of the WBV Profile of the patient's blood against a benchmark as well as an interpretive guide. The results are typically provided within 24 hours. For more information about the program, doctors can contact the Company at

Rheologics believes that its whole blood viscosity test will be comparable to cholesterol testing in terms of its commercial reach and clinical impact. The U.S. market for the LDL cholesterol testing is estimated at 65 million tests per year, while the U.S. market for HDL cholesterol tests is estimated at 100 million tests per year.

Cardiovascular disease is one of the leading causes of death in the United States, affecting more than 62 million Americans and claiming the lives of nearly one million people in the U.S. per year. Globally, over 17 million people die from vascular diseases, mostly heart attacks and strokes.

The Rheolog® is an FDA IDE-exempt device approved for research and for providing additional information in the interpretation of a disease condition and therefore is not covered by insurance plans.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventative diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.

Contact Information